IDH2 Antibody

1. pharmacogenetics: observations uncover a mechanism of acquired resistance to a targeted therapy and underscore the importance of 2-hydroxyglutarate production in the pathogenesis of IDH2-mutant malignancies PMID:29950729
2. We validated the presence of IDH2 R172 hotspot mutations and PIK3CA hotspot mutations in 100% and 67% of solid papillary breast carcinoma with reverse polarity tested, respectively PMID:29603332
3. Enasidenib reduces 2-hydroxyglutarate levels in patients with relapsed or refractory (R/R) acute myeloid leukemia harboring either IDH2-R140 or IDH2-R172 mutations PMID:29243965
4. IDH2 mutation is associated with glioma progression. PMID:29016871
5. This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre- or post-transplant therapy PMID:28687222
6. IDH2(mut) patients had a higher risk of leukemic transformation. The co-occurrence of DNMT3A or SRSF2 mutations was found to be increased in IDH2(mut) patients. IDH2 mutations were associated with significantly worse OS and LFS amongst patients with low-risk MDS by IPSS grouping. PMID:29549529
7. IDH2 R172 mutations may be the only variants present in angioimmunoblastic T-cell lymphoma because of their capacity to produce significant amounts of the oncometabolite 2-hydroxyglutarate in the cell of origin of this disease PMID:27956631
8. IDH2 mutation is associated with 1p19q co-deletion diffuse glioma. PMID:28340142
9. data confirm MLL-PTD and, to a lesser extent, FLT3-ITD as common events in +11 AML.6, 7, 8 However, the high mutation frequencies of U2AF1 and genes involved in methylation (DNMT3A, IDH2) have hitherto not been reported in +11 AML PMID:27435003
10. We demonstrate that the majority of histologically defined sinonasal undifferentiated carcinomas are characterized by IDH2 R172X mutations and overexpression of mutant protein PMID:28084339
11. The found of this study that IDH12 mutation status had greater impact than histological and other genomic features on miRNA expression patterns. PMID:28091987
12. demonstrate the presence of the IDH2 p.R172K/S mutation in patients with cutaneous localizations of angioimmunoblastic T-cell lymphomas. PMID:28945625
13. IDH2 mutation is associated with high-grade gliomas. PMID:27353503
14. these results suggest a potential relationship between SIRT3 enzymatic activity, IDH2-K413 acetylation-determined dimerization, and a cancer-permissive phenotype PMID:28536275
15. There are frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. PMID:28493366
16. Results identified IDH2 rs11540478 as a new susceptibility locus for lung cancer. PMID:27649069
17. Functional studies demonstrated that IDH2 and PIK3CA hotspot mutations are likely drivers of solid papillary carcinoma with reverse polarity PMID:27913435
18. IDH2 mutation is associated with polycythemia vera and essential thrombocythemia. PMID:27997717
19. Mutations in some enzymes of the TCA cycle: Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH) and fumarate hydratase (FH) are associated with the accumulation of metabolites that are able to influence many aspects of cancer development and progression and for this reason are termed onco-metabolites. PMID:27528759
20. Only three IDH2(R172) mutation cases were detected in this series of patients with astrocytomas and oligodendrogliomas PMID:27780605
21. these data suggest that IDH2 may be a tumor suppressor in that its loss may promote malignant progression of gastric cancer via NF-kappaB-dependent increases in MMP7 activity. PMID:26553362
22. Genetic variants in IDH2 were found in patients with hematological malignancies. PMID:27591990
23. CASP8 rs3769823 and IDH2 rs4561444 were as the potential functional variants in high-linkage disequilibrium with these single nucleotide polymorphisms, respectively. The IDH2 mRNA levels were down-regulated in oesophageal squamous cell carcinoma. PMID:26635288
24. Results revealed that the expression of IDH2 was inversely correlated with pathological grade and metastasis in osteosarcoma and its downregulation may exacerbate malignant progression via increased NF-kappaB and MMP-9 activity. PMID:26782630
25. mechanistic studies of IDH2 mutations in gliomas (review) PMID:26188014
26. IDH2 mutation is associated with higher risk of malignant transformation in low-grade glioma. PMID:26780338
27. Results show that IDH2 is hypermethylated in glioma and the mutations are mutually exclusive with PTEN, P53 and ATRX mutations in the tumors. PMID:27245697
28. The Isocitrate dehydrogenase is mutated at a key active site arginine residue (Arg172 in IDH2) in many cancers, leading to the synthesis of the oncometabolite (R)-2-hydroxyglutarate (2HG). PMID:26761588
29. Down regulation of IDH2 may promote HCC cell invasion via NF-x03BA;B-dependent increases in MMP9 activity. IDH2 may be a potential therapeutic target for HCC PMID:26646705
30. With the advent of large-scale genome sequencing technology, molecular genetic alterations in IDH2 promoter have now been identified in the majority of oligodendrogliomas PMID:26545048
31. IDH2 mutations and their functions in human tumors (review) PMID:26147657
32. Glioblastomas with IDH1-m should be considered a different entity from the IDH1-wt, as their natural history and prognosis differ. In the near future we should be classified glioblastomas based on the presence of the IDH1 mutation PMID:26194445
33. The IDH2 mutations are associated with improved survival in patients with Glioblastomas. PMID:26945349
34. IDH2 mutation produced more 2-HG than IDH1 mutation. PMID:26669865
35. Authors suggest 2HG as an analytic marker (in serum, urine, or biopsies) predicting malignancy of breast cancer in all patients. PMID:26007236
36. report of clinicopathological characteristics of the gliomas with IDH2 mutations including two cases of primary GBM carrying a novel missense IDH2 mutation (c. 484C>T, p. P162S) PMID:25495392
37. suggest that mutations in isocitrate dehydrogenases IDH1/2 lead to a local block in osteogenic differentiation during skeletogenesis causing the development of benign cartilaginous tumors. PMID:26046462
38. IDH2 mutations are associated with normal cytogenetics and type A NPM1 mutations in Acute Myeloid Leukaemia. PMID:25987093
39. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. PMID:26268241
40. IDH2 mutation is associated with response to therapy in anaplastic astrocytoma. PMID:24993250
41. IDH2 mutations are associated with myelodysplastic syndromes. PMID:24936872
42. IDH2 gene SNPs exhibited significant association with death risk in hepatocellular carcinoma patients. PMID:25355558
43. A review summarizes the function of mutated vs. wild-type IDH enzymes and the role of IDH2 mutations in gliomas. PMID:25078896
44. Gliomas were classified into five principal groups on the basis of three tumor markers including IDH2. The groups had different ages at onset, overall survival, and associations with germline variants. PMID:26061753
45. Isocitrate dehydrogenase 2 mutation is associated with infiltrative glioma. PMID:24860178
46. When normalized with the respective WT-IDH cells, the general metabolic shifts of MT-IDH1 and IDH2 were almost opposite. Lactate level was lower in MT-IDH2 cells which produced more 2-HG than MT-IDH1 cells. PMID:25251602
47. we propose the TCM compounds, precatorine and abrine, as potential candidates as lead compounds for further study in drug development process with the IDH2 R140Q mutant protein against cancer PMID:24995286
48. These results indicated lithium chloride could decrease the proliferation and migration potential of C6 glioma cells harboring IDH2 mutation. PMID:24549719
49. The recent discoveries reported here help understanding of the role of the IDH1/2 mutations in chondrosarcomas. IDH mutational status serves as a molecular signature to differentiate chondrosarcomas from other sarcomas with cartilaginous element. PMID:24867810
50. knowledge of the IDH mutation status has had significant translational implications, and diagnostic tools are being used to monitor its expression and function[Review] PMID:23373447

Show More

Hide All

HGNC: 5383

UNIGENE: Hs.596461

KEGG: hsa:3418

STRING: 9606.ENSP00000331897

OMIM: 137800